Continuous endpoints in Bayesian two-stage designs

References

• An, M. W., Mandrekar, S. J., Branda, M. E., Hillman, S. L., Adjei, A. A., Pitot, H. C., Goldberg, R. M., Sargent, D. J. (2011). Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials. Clinical Cancer Research 17:6592–6599.
   PubMed Web of Science ®Google Scholar
• Arellano-Valle, R. B., Branco, M. D., Genton, M. G. (2006). A unified view on skewed distributions arising from selections. Canadian Journal of Statistics 34:581–601.
   Web of Science ®Google Scholar
• Azzalini A. (2014). The Skew–Normal and Related Families. IMS Monographs Series. Cambridge, UK: Cambridge University Press.
   Google Scholar
• Berger, J. O., Wolpert, R. L. (1988). The likelihood principle: a review, generalizations, and statistical implications. IMS Lecture Notes Monogr. Ser.
   Google Scholar
• Brutti, P., De Santis, F., Gubbiotti, S. (2008). Robust Bayesian sample size determination in clinical trials. Statistics Medicine 27:2290–2306.
   PubMed Web of Science ®Google Scholar
• De Santis, F. (2006). Sample size determination for robust Bayesian analysis. Journal of the American Statistical Association 101:278–291.
   Web of Science ®Google Scholar
• Dhani, N., Tu, D., Sargent, D. J., Seymour, L., Moore, M. J. (2009). Alternate endpoints for screening phase II studies. Clinical Cancer Research 15:1873–1882.
   PubMed Web of Science ®Google Scholar
• Gut, A. (2009). An Intermediate Course in Probability. New York: Springer-Verlag.
   Google Scholar
• Karrison, T. G., Maitland, M. L., Stadler, W. M., Ratain, M. J. (2007). Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. Journal of National Cancer Institute 99:1455–1461.
   PubMed Web of Science ®Google Scholar
• Lavin, P. T., (1981). An alternative model for the evaluation of antitumor activity. Cancer Clinical Trials 4:451–457.
   PubMedGoogle Scholar
• Sambucini, V. (2008). A Bayesian predictive two-stage design for phase II clinical trials. Statistics in Medicine 27:1199–1224.
   PubMed Web of Science ®Google Scholar
• Sahu, S. K., Smith, T. M. F. (2006). A Bayesian method of sample size determination with practical applications. Journal of the Royal Statistical Society A 169:235–253.
   Web of Science ®Google Scholar
• Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Control Clinical Trials 10:1–10.
   PubMedGoogle Scholar
• Snapinn, S. M., Jiang, Q. (2007). Responder analyses and the assessment of a clinically relevant treatment effect. Trials 8:1–6.
   PubMed Web of Science ®Google Scholar
• Spiegelhalter, D. J., Abrams, K. R., Myles, J. P. (2006). Bayesian Approaches to Clinical Trials and Health-care Evaluation. New York: Wiley.
   Google Scholar
• Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., Gwyther, S. G. (2000). New guidelines to evaluate the response to treatment in solid tumors. Journal of National Cancer Institute 92:205–216.
   PubMed Web of Science ®Google Scholar
• Wang, F., Gelfand, A. E. (2002). A simulation-based approach to Bayesian sample size determination for performance under a given model and for separating models. Statistics Science 17:193–208.
   Web of Science ®Google Scholar
• Whitehead, J., Valdes-Marquez, E., Lissmats, A. (2009). A simple two-stage design for quantitative responses with application to a study in diabetic neuropathic pain. Pharmaceutical Statistics 8:125–135.
   PubMed Web of Science ®Google Scholar
• Wason, J. M. S., Mander, A. P., Eisen, T. G. (2011). Reducing the sample sizes in two-stage phase II cancer trials by using continuous endpoints. European Journal of Cancer 47:983–989.
   PubMed Web of Science ®Google Scholar
• Wason, J. M., Mander, A. P. (2012). Minimizing the maximum expected sample size in two-stage Phase II clinical trials with continuous outcomes. Journal Biopharmaceutical Statistics 22:836–852.
   PubMed Web of Science ®Google Scholar
• Wason, J. M., Mander, A. P., Thompson, S. G. (2012). Optimal multistage designs for randomised clinical trials with continuous outcomes. Statistics Medicine 31:301–312.
   PubMed Web of Science ®Google Scholar